Assessing the economic impact of advanced testing for brain infections after surgery
Economic Impact of Metagenomic Next-generation Sequencing Versus Traditional Bacterial Culture Directed CNSIs Diagnosis and Therapy in Post-neurosurgical Patients Using a Decision Analysis Model
NA · Capital Medical University · NCT05887037
This study is testing if a new advanced test for brain infections after surgery can be more effective and cost-efficient than the usual methods.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 204 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Capital Medical University (other) |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT05887037 on ClinicalTrials.gov |
What this trial studies
This study evaluates the economic implications of using metagenomic next-generation sequencing (mNGS) compared to traditional bacterial cultures for diagnosing central nervous system infections (CNSIs) in patients who have undergone neurosurgery. The research focuses on the effectiveness and cost-efficiency of mNGS in identifying pathogens responsible for CNSIs, which are serious complications that can lead to poor patient outcomes. By analyzing the clinical application value of mNGS, the study aims to provide insights into its potential benefits over conventional methods, particularly in terms of diagnosis speed and accuracy.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who have developed central nervous system infections following neurosurgery.
Not a fit: Patients with unqualified samples or those whose clinicians deem unsuitable for the study will not benefit from this research.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy and reduced healthcare costs for patients with central nervous system infections.
How similar studies have performed: Other studies have shown promising results with metagenomic next-generation sequencing in diagnosing infections, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: ·Central nervous system infections Exclusion Criteria: * Unqualified samples * Patients and their families refused to sign the informed consent * The clinician considered the case unsuitable for inclusion in the study
Where this trial is running
Beijing, Beijing
- Linlin Zhang — Beijing, Beijing, China (RECRUITING)
Study contacts
- Study coordinator: Jian-Xin Zhou, MD
- Email: zhoujx.cn@icloud.com
- Phone: 8610 63926888
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Central Nervous System Infections, Central nervous system infections, Metagenomic next-generation sequencing